恩替卡韦联合水飞蓟宾治疗乙型肝炎肝硬化的效果及对肝纤维化和微炎症状态的影响

To Explore the Effect of Entecavir Combined with Silibinin in the Treatment of Hepatitis B Cirrhosis and its Influence on Liver Fibrosis and Micro Inflammation

目的评价恩替卡韦联合水飞蓟宾治疗乙型肝炎肝硬化的效果及对肝纤维化和微炎症状态的影响。方法回顾性评价2022年1~12月在本院就诊的乙型肝炎肝硬化患者80例,包括恩替卡韦联合水飞蓟宾组(联合组)和恩替卡韦单药组(对照组)。两组随访时间均为3个月。结果两组患者的性别、年龄、病程和BMI不存在统计学差异(P>0.05)。治疗前,两组患者的层粘连蛋白(LN)、透明乐酸(HA)、Ⅰ型前胶原(PCⅠ)及Ⅳ型胶原(Ⅳ-C)水平基本一致;治疗3个月后,联合组的LN、HA、PCⅠ及Ⅳ-C水平显著低于对照组(P<0.05)。治疗前,两组患者的白细胞介素-2(IL-2)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)基本一致;治疗3个月后,联合组血清中IL-2、IL-6和TNF-α水平低于对照组(P<0.05)。结论恩替卡韦联合水飞蓟宾对乙型肝炎肝硬化患者肝纤维化和微炎症状态具有改善作用,具有良好的临床疗效。

Objective To evaluate the effect of entecavir combined with silybin in the treatment of hepatitis B cirrhosis and its clinical effect on liver fibrosis and microinflammatory state.Methods Retrospective evaluation 80 patients with hepatitis B cirrhosis who visited our hospital from January 2022 to December 2022 including entecavir in combination with silybin(Joint groups)and usual way(control group).Follow-up time was available in both groups for 3 Months.Results There was no statistically significant difference of sex,age,disease course and BMI of patients in both groups(P>0.05).Before treatment,The level is basically the same of Laminin(LN),transparent lesour(HA),typeⅠcollagen(PCⅠ)and V type collagen(Ⅳ-C)in two groups of patients;treatment for 3 months later,The level of the joint groups is significant Lower than the control group about LN,HAS,PCⅠandⅣ-C(P<0.05).Before treatment,two groups of patients'Interleukin-2(IL-2),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)was basically the same;treatment for 3 months later,IL-2,IL-6,TNF-αlevel of the joint groups is lower than the control group(P<0.05).Conclusion Entecavir combined with silybin has an improving effect on liver fibrosis and microinflammation in patients with hepatitis B cirrhosis,and has significant clinical efficacy.